ライフサイエンスコーパス: squamous cell cancer

1 and treatment for occult metastasis in oral squamous cell cancer.

2 ection and therapeutic targets of esophageal squamous cell cancer.

3 ntinel nodes in patients with cT1-T2 N0 oral squamous cell cancer.

4 ng cART in an HIV-1-infected patient who had squamous cell cancer.

5 iene receptors was deregulated in esophageal squamous cell cancer.

6 squamous dysplasia and inflammation-mediated squamous cell cancer.

7 melanoma cancer, either basal cell cancer or squamous cell cancer.

8 t are frequently altered in human esophageal squamous cell cancer.

9 marker in breast carcinoma and oropharyngeal squamous cell cancer.

10 nce the effect of chemotherapy on esophageal squamous cell cancers.

11 racterized by an increased susceptibility to squamous cell cancers.

12 d with arterial aneurysms, autoimmunity, and squamous cell cancers.

13 mutations found in the p53 gene of basal and squamous cell cancers.

14 ression was lost concurrently with NOTCH1 in squamous cell cancers.

15 eChips were used to profile 59 head and neck squamous cell cancers.

16 n, a hallmark feature of well-differentiated squamous cell cancers.

17 multiple genes that are mutated in cutaneous squamous cell cancers.

18 treatment of locally advanced head and neck squamous cell cancers.

19 orly differentiated cancer specimens than in squamous cell cancers.

20 inoid with preclinical antitumor activity in squamous cell cancers.

21 %) ciclosporin users developed a total of 20 squamous cell cancers.

22 These include 2 with squamous cell cancers, 2 with melanoma, 1 with renal cel

23 ge: 60.1 years; adenocarcinoma: 25 patients; squamous cell cancer: 21 patients).

24 fifteen patients had adenocarcinoma, 16 had squamous cell cancer, 6 had another form of esophageal t

25 ssion also decreased, especially in invasive squamous cell cancer (70% loss).

26 Patients characteristics were as follows: squamous cell cancer, 90% versus 85%; weight loss greate

27 Squamous cell cancers account for more than half of all

28 Esophageal squamous cell cancer accounts for more than 90% of cases

29 quency of 0.7 (prostate cancer) to 9.9 (lung squamous cell cancer), all tumor types from white patien

30 iopsy samples of 19 patients with esophageal squamous cell cancer and 9 sex- and age-matched patients

31 rmine the molecular mechanisms of esophageal squamous cell cancer and inflammation-mediated carcinoge

32 nd invasive epithelium from human esophageal squamous cell cancer and prostatic adenocarcinoma.

33 e CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to assess activ

34 Human squamous cell cancers are the most common epithelially d

35 be considered, and basket trials in perineal squamous cell cancers are warranted.

36 n found to be efficacious for basal cell and squamous cell cancers, as well as cutaneous T-cell lymph

37 d patients with non-metastatic head and neck squamous cell cancer between Jan 1, 1980, and Dec 31, 20

38 ving outcomes of patients with head and neck squamous cell cancer, both human papilloma virus-associa

39 body used for the treatment of head and neck squamous cell cancer, but despite the benefits of adding

40 esistant colorectal cancer and head and neck squamous cell cancer cell lines and in tumors from color

41 al analyses, showed that human head and neck squamous cell cancer cells express heretofore unrecogniz

42 s were significantly increased in esophageal squamous cell cancer compared to control mucosa (p < 0.0

43 Squamous cell cancers comprise the most common type of h

44 Conversely, squamous cell cancer comprised 60% of the rapid DT group

45 cently demonstrated that human head and neck squamous cell cancers contain a tumorigenic, so-called c

46 Among human malignancies, head and neck squamous cell cancer displays a marked predilection for

47 Among patients with early-stage oral squamous-cell cancer, elective neck dissection resulted

48 onal PIK3R1 and mTOR SNPs in 1116 esophageal squamous cell cancer (ESCC) patients and 1117 cancer-fre

49 ents with esophageal adenocarcinoma (EAC) or squamous cell cancer (ESCC) present with advanced, incur

50 10 was compared with uptake in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promy

51 treatment of locally advanced head and neck squamous cell cancer has advanced greatly in recent year

52 se in incidence of a subset of head and neck squamous cell cancers (HNCs) in numerous geographic regi

53 es for patients with high-risk head and neck squamous cell cancer (HNSCC) after surgical resection by

54 Patients with head and neck squamous cell cancer (HNSCC) are at a greater risk of de

55 The treatment paradigms for head and neck squamous cell cancer (HNSCC) are changing due to the eme

56 owth factor receptor-dependent head and neck squamous cell cancer (HNSCC) cell lines and a synthetic

57 ternalization of HN-1 by human head and neck squamous cell cancer (HNSCC) cells suggests that HN-1 is

58 GFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multi

59 ll cell lung cancer (NSCLC) or head and neck squamous cell cancer (HNSCC) compared with inflammatory

60 Head and neck squamous cell cancer (HNSCC) is associated with a higher

61 Head and neck squamous cell cancer (HNSCC) occurs at higher rates amon

62 umor-free" surgical margins of head and neck squamous cell cancer (HNSCC) patients is an independent

63 ce severe acute toxicities for head and neck squamous cell cancer (HNSCC) patients treated with conco

64 ival in patients with advanced head and neck squamous cell cancer (HNSCC) remains dismal.

65 Appropriate treatment of head and neck squamous cell cancer (HNSCC) remains one of the most dif

66 be involved in development of head and neck squamous cell cancer (HNSCC), yet current evidence is la

67 urrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

68 prognostic value for resected head and neck squamous cell cancer (HNSCC).

69 the follow-up of patients with head and neck squamous cell cancer (HNSCC).

70 th the etiology of a subset of head and neck squamous cell cancer (HNSCC).

71 Head and neck squamous cell cancers (HNSCC) have a high local recurren

72 ctor, is found elevated in all head and neck squamous cell cancers (HNSCC).

73 cohorts: urothelial carcinoma, head and neck squamous-cell cancer (HNSCC), non-small-cell lung cancer

74 he tumorigenesis and progression of cervical squamous cell cancer; however, the mechanisms underlying

75 del of human papillomavirus (HPV)-associated squamous cell cancers, HPV16 E6 and E7 oncogenes and E1

76 )-2 has been demonstrated to protect against squamous cell cancer in many studies.

77 egression up to 50% in the treatment of lung squamous cell cancer in mice.

78 insights into the molecular pathogenesis of squamous cell cancers in general.

79 acilitate the formation of HPV E6/E7-induced squamous cell cancers in mice using a transposon-mediate

80 pregulating TAp63 and preventing or treating squamous cell cancers in the general non-FA population.

81 therapy in patients with advanced-stage oral squamous cell cancers in the US.

82 e genus beta to the development of cutaneous squamous cell cancer is still under debate.

83 How monoubiquitinated FANCD2 suppresses squamous cell cancers is unknown.

84 most frequent of the HPV types detected when squamous-cell cancer is diagnosed and the type most stro

85 NUT midline carcinoma (NMC), a subtype of squamous cell cancer, is one of the most aggressive huma

86 rd of care in locally advanced head and neck squamous cell cancer (LAHNSCC).

87 of skin cancers including basal cell cancer, squamous cell cancer, lentigo maligna melanoma and cutan

88 In contrast, the squamous cell cancer-like (SCCL) subtype uniformly expre

89 ment for Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Cancer (LSCC) and the ERK2-VTX11e treatmen

90 olon cancer, breast cancer, prostate cancer, squamous cell cancer, lymphoma, and leiomyosarcoma, sugg

91 In both microinvasive and invasive cervical squamous cell cancer miR-155 expression remained high (8

92 ng dose-limiting toxicity in a head and neck squamous cell cancer murine model.

93 prove outcomes for patients with oral cavity squamous cell cancer (OCSCC).

94 (ATZ), 1 (0.03%) with pouch lymphoma, 3 with squamous cell cancer of the ATZ, and 23 with dysplasia (

95 in patients with prior chemotherapy-treated squamous cell cancer of the cervix.

96 mitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN).

97 f docetaxel, cisplatin, and fluorouracil for squamous cell cancer of the head and neck (SCCHN) and to

98 irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase

99 The overall survival of patients with squamous cell cancer of the head and neck has not signif

100 nd 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck.

101 The risk of squamous cell cancer of the skin is increased by ciclosp

102 nt radiation in patients with poor-prognosis squamous cell cancers of the anal canal.

103 s a major risk factor for the development of squamous cell cancers of the cervix and of the head and

104 eIF4E in the tumors and surgical margins of squamous cell cancers of the larynx and to determine the

105 med on 54 patients who underwent surgery for squamous cell cancers of the larynx.

106 were strongly linked with an excess risk of squamous-cell cancers of the buccal cavity and skin.

107 ly when applied to HPV-related oropharyngeal squamous cell cancer (OPSCC), leading to calls for a new

108 havior of a number of cancers including oral squamous cell cancer (OSCC), and increased expression of

109 Among squamous cell cancers, p53 mutations were detected signi

110 e novel approaches to treating head and neck squamous cell cancer, particularly the introduction of b

111 sponse and survival outcome in head and neck squamous cell cancer patients (HNSCC).

112 inses from a separate group of head and neck squamous cell cancer patients contained detectable telom

113 ents were significantly higher than those of squamous cell cancer patients.

114 nstructs that mimicked the initial stages of squamous cell cancer progression.

115 part in suppressing the incipient stages of squamous cell cancer progression.

116 mutations occur in approximately 4% of lung squamous cell cancer (SCC) where the tyrosine kinase inh

117 Although it is known that squamous cell cancers (SCC) are caused by UV light, the

118 X expression has been reported in esophageal squamous cell cancers (SCC).

119 Squamous cell cancers (SCCs) of the head and neck, esoph

120 atients with FA have a high baseline risk of squamous cell cancers (SCCs) of the head, neck, and esop

121 ia in human head and neck and uterine cervix squamous cell cancers (SCCs).

122 ed by its pathogenic mutations in esophageal squamous cell cancers (SCCs).

123 A rise in incidence of oropharyngeal squamous cell cancer--specifically of the lingual and pa

124 26 of 35 (80%) primary, fresh, head and neck squamous cell cancer specimens and 3 of 6 head and neck

125 Esophageal cancer is a prototypic squamous cell cancer that carries a poor prognosis, prim

126 L2-cre;p120ctnLoxP/LoxP mice, which develop squamous cell cancers that resemble human ESCC, we visua

127 In head and neck squamous cell cancer, the human epidermal growth factor

128 kpoint blockade (ICB) therapy for esophageal squamous cell cancer, the key immune cell populations th

129 lls as a platform to recapitulate esophageal squamous cell cancer, thereby providing insights into th

130 otherapeutic agent usedagainst head and neck squamous cell cancer to date.

131 To examine E-cadherin loss in squamous cell cancers, we used primary human esophageal

132 with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction

133 vival outcomes in lung cancer, especially in squamous cell cancers where p53 abnormalities are more c

134 in BCC patients treated with Smo inhibitor, squamous cell cancers with RAS/MAPK activation emerged f

135 In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combi